Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct 24;5(6):e364.
doi: 10.1212/NXG.0000000000000364. eCollection 2019 Dec.

Migraine polygenic risk score associates with efficacy of migraine-specific drugs

Lisette J A Kogelman  1 , Ann-Louise Esserlind  1 , Anne Francke Christensen  1 , Swapnil Awasthi  1 , Stephan Ripke  1 , Andres Ingason  1 , Olafur B Davidsson  1 , Christian Erikstrup  1 , Henrik Hjalgrim  1 , Henrik Ullum  1 , Jes Olesen  1 , Thomas Folkmann Hansen  1 ; DBDS Genomic Consortium, The International Headache Genetics Consortium
Affiliations

Migraine polygenic risk score associates with efficacy of migraine-specific drugs

Lisette J A Kogelman et al. Neurol Genet. .

Abstract

Objective: To assess whether the polygenic risk score (PRS) for migraine is associated with acute and/or prophylactic migraine treatment response.

Methods: We interviewed 2,219 unrelated patients at the Danish Headache Center using a semistructured interview to diagnose migraine and assess acute and prophylactic drug response. All patients were genotyped. A PRS was calculated with the linkage disequilibrium pred algorithm using summary statistics from the most recent migraine genome-wide association study comprising ∼375,000 cases and controls. The PRS was scaled to a unit corresponding to a twofold increase in migraine risk, using 929 unrelated Danish controls as reference. The association of the PRS with treatment response was assessed by logistic regression, and the predictive power of the model by area under the curve using a case-control design with treatment response as outcome.

Results: A twofold increase in migraine risk associates with positive response to migraine-specific acute treatment (odds ratio [OR] = 1.25 [95% confidence interval (CI) = 1.05-1.49]). The association between migraine risk and migraine-specific acute treatment was replicated in an independent cohort consisting of 5,616 triptan users with prescription history (OR = 3.20 [95% CI = 1.26-8.14]). No association was found for acute treatment with non-migraine-specific weak analgesics and prophylactic treatment response.

Conclusions: The migraine PRS can significantly identify subgroups of patients with a higher-than-average likelihood of a positive response to triptans, which provides a first step toward genetics-based precision medicine in migraine.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Association of the polygenic risk score with acute treatment response
ORs and the 95% CI are shown on the left-hand side, and the corresponding forest plot is shown on the right-hand side. An OR below 1 represents a lower response rate to the drug. An OR above 1 represents a higher response rate to the drug. Migraine-specific acute treatment includes both triptan and ergotamine, as both are acting on the same 5-HT1B/D receptors. Migraine nonspecific treatment is represented by the weak analgesics. CI = confidence interval; OR = odds ratio.
Figure 2
Figure 2. Associations of the polygenic risk score with prophylactic treatment response
ORs and the 95% CI are shown on the left-hand side, and the corresponding forest plot is shown on the right-hand side. An OR below 1 represents a lower response rate to the drug. An OR above 1 represents a higher response rate to the drug. Acute treatment includes both triptan and ergotamine, as both are acting on the same 5-HT1B/D receptors. Prophylactic treatment response includes all questioned treatments summed up (positive response to any prophylactic drug vs response to none). ACE = angiotensin-converting enzyme; CI = confidence interval; OR = odds ratio.
Figure 3
Figure 3. Replication of the association of the polygenic risk score (PRS) with acute treatment response
Odds ratio by PRS within each 20 percentiles for n = 5,616 triptan users in the Danish Blood Donor Study replication cohort.
See this image and copyright information in PMC

Comment in

References

    1. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992;33:1569–1582. - PubMed
    1. Kobylecki CJ, Jakobsen KD, Hansen T, Jakobsen IV, Rasmussen HB, Werge T. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study. Neuropsychobiology 2009;59:222–226. - PubMed
    1. Lewis CM, Vassos E. Prospects for using risk scores in polygenic medicine. Genome Med 2017;9:96. - PMC - PubMed
    1. Glahn DC, McIntosh AM. Using polygenic risk scores to establish endophenotypes: considerations and current constraints. Biol Psychiatry Cogn Neurosci Neuroimaging 2017;2:113–114. - PMC - PubMed
    1. International Consortium on Lithium Genetics; Amare AT, Schubert KO, Hou L, et al. . Association of polygenic score for schizophrenia and HLA antigen and inflammation genes with response to lithium in bipolar affective disorder: a genome-wide association study. JAMA Psychiatry 2018;75:65–74. - PMC - PubMed